Literature DB >> 17146092

Recognition and management of neuropsychiatric complications in Parkinson's disease.

Florian Ferreri1, Catherine Agbokou, Serge Gauthier.   

Abstract

Parkinson's disease is primarily considered a motor disease characterized by rest tremor, rigidity, bradykinesia and postural disturbances. However, neuropsychiatric complications, including mood and anxiety disorders, fatigue, apathy, psychosis, cognitive impairment, dementia, sleep disorders and addictions, frequently complicate the course of the illness. The pathophysiologic features of these complications are multifaceted and include neuropathophysiologic changes of a degenerative disease, exposure to antiparkinsonian treatments and emotional reactions to having a disabling chronic illness. Changes in mental status have profound implications for the well-being of patients with Parkinson's disease and of their caregivers. Treatment is often efficacious but becomes a challenge in advanced stages of Parkinson's disease. In this article, we review the key clinical features of neuropsychiatric complications in Parkinson's disease as well as what is known about their epidemiologic characteristics, risk factors, pathophysiologic features and management.

Entities:  

Mesh:

Year:  2006        PMID: 17146092      PMCID: PMC1660590          DOI: 10.1503/cmaj.060542

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  57 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 2.  Current concepts in the diagnosis and management of Parkinson's disease.

Authors:  Mark Guttman; Stephen J Kish; Yoshiaki Furukawa
Journal:  CMAJ       Date:  2003-02-04       Impact factor: 8.262

Review 3.  Behavioral complications of drug treatment of Parkinson's disease.

Authors:  J L Cummings
Journal:  J Am Geriatr Soc       Date:  1991-07       Impact factor: 5.562

Review 4.  Cognitive deficits in Parkinson's disease.

Authors:  B Dubois; B Pillon
Journal:  J Neurol       Date:  1997-01       Impact factor: 4.849

5.  The measurement of fatigue: a new instrument.

Authors:  J E Schwartz; L Jandorf; L B Krupp
Journal:  J Psychosom Res       Date:  1993-10       Impact factor: 3.006

6.  Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease.

Authors:  I Nakano; A Hirano
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

Review 7.  Anxiety and Parkinson's disease.

Authors:  I H Richard; R B Schiffer; R Kurlan
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1996       Impact factor: 2.198

8.  Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study.

Authors:  R A Maricle; J G Nutt; R J Valentine; J H Carter
Journal:  Neurology       Date:  1995-09       Impact factor: 9.910

9.  Buspirone, Parkinson's disease, and the locus ceruleus.

Authors:  C L Ludwig; D R Weinberger; G Bruno; M Gillespie; K Bakker; P A LeWitt; T N Chase
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

10.  Evidence for atypical depression in Parkinson's disease.

Authors:  R B Schiffer; R Kurlan; A Rubin; S Boer
Journal:  Am J Psychiatry       Date:  1988-08       Impact factor: 18.112

View more
  8 in total

1.  Management of sexual dysfunction in Parkinson's disease.

Authors:  Gila Bronner; David B Vodušek
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

Review 2.  Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Authors:  Thomas N Chase
Journal:  Neurotox Res       Date:  2010-05-15       Impact factor: 3.911

Review 3.  Therapy-resistant symptoms in Parkinson's disease.

Authors:  Ruxandra Julia Vorovenci; Roberta Biundo; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2015-09-26       Impact factor: 3.575

Review 4.  Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.

Authors:  Nandakumar S Narayanan; Robert L Rodnitzky; Ergun Y Uc
Journal:  Rev Neurosci       Date:  2013       Impact factor: 4.353

5.  Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.

Authors:  Nathan Herrmann; Connie Marras; Hadas D Fischer; Xuesong Wang; Geoff M Anderson; Paula A Rochon
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

6.  Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via transcription factor EB-dependent autophagy in mutant α-synucleinA53T model of Parkinson's disease.

Authors:  Kanmin Mao; Jialong Chen; Honglin Yu; Huihui Li; Yixian Ren; Xian Wu; Yue Wen; Fei Zou; Wenjun Li
Journal:  Aging Cell       Date:  2020-05-31       Impact factor: 9.304

7.  Cognitive Behavioral Therapy Plus a Serious Game as a Complementary Tool for a Patient With Parkinson Disease and Impulse Control Disorder: Case Report.

Authors:  Teresa Mena-Moreno; Lucero Munguía; Rosario Granero; Ignacio Lucas; Almudena Sánchez-Gómez; Ana Cámara; Yaroslau Compta; Francesc Valldeoriola; Fernando Fernandez-Aranda; Anne Sauvaget; José M Menchón; Susana Jiménez-Murcia
Journal:  JMIR Serious Games       Date:  2022-09-09       Impact factor: 3.364

8.  Effect of dopamine therapy on nonverbal affect burst recognition in Parkinson's disease.

Authors:  Julie Péron; Didier Grandjean; Sophie Drapier; Marc Vérin
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.